ACM Biolabs

ACM Biolabs - Next-generation polymer-based nanoparticle delivery technology
Manage Cookie Consent
We cookies to optimize performance and provide information. Consenting to these technologies will allow us to process data such as browsing behavior or unique IDs on this site. Not consenting or withdrawing consent, may adversely affect certain features and functions.
Functional- [x] Functional Always active

Why we do it

We want to change the status quo of lipid-based targeted delivery of various drug payloads which is limiting its broader therapeutic applications.

How we do it

We are pioneering next next-generation polymer-based delivery technology platform that is able to deliver multiple drug payloads by targeting specific tissues or cells and potentially overcome well-known challenges faced by lipid nanoparticle-based products. Artificial cell membranes (or “ACMs”) are the building blocks of our patented technology. These ACMs are composed of block co-polymers to create nano delivery carriers. We have spent over 15 years perfecting and patenting scalable process for creating these modular delivery platform for various payloads.

What we do

ACM Biolabs’ Tunable Platform (ATP™) is a polymer/lipid hybrid, non-viral delivery platform that offers the flexibility to deliver multiple payloads including oligonucleotides, small molecules, proteins, and mRNA. ATP™ is thermostable, allowing mRNA storage at 4°C in contrast to the current lipid nanoparticle-based delivery systems that require ultra-low cold storage. ACM Biolabs has programs targeting multiple organs, tissues, and immune cells.
Scientific Advisors
Board of Directors
Business Development
Madhavan Nallani
Pierre Vandepapelière
Katherine Schultheis
Gaurav Sinsinbar
Anivind Kaur Bindra
Salmah Humairoh Binte Zamri
Eunice Yoong Eng Chia
We are looking for highly motivated specialists – take a look at our career offers

ATP TM stands for ACM Biolabs Tunable Platform.

Technology Platform

Artificial cell membranes (or “ACMs”) are the building blocks of our patented technology. These ACMs are composed of block co-polymers to create nano delivery carriers. We have spent over 15 years perfecting and patenting scalable process for creating these modular delivery platform for various payloads.
Our data show that ATPs can deliver multiple payloads including oligonucleotides, small molecules, proteins, and mRNA. ATP™ is thermostable, allowing mRNA storage at 4°C in contrast to the current lipid nanoparticle-based delivery systems that require ultra-low cold storage. ATP™has the potential to transform targeted delivery of various drug payloads.

Potential to revolutionize the therapeutic delivery to cells and tissues.

Therapeutic Approach

At ACM Biolabs, we are developing innovative medicines using our targeted ATP™delivery platform. Our non-viral, ATP™-based nanocarriers are suitable for diverse drug payloads with various routes of administration, including mucosal delivery.
ATP™can target the right tissues and cells.This powerful toolbox has the potential to address a broad range of diseases.
The ATP™platform has been proven safe in clinical trials (see:Clinical Trial ID NCT05385991). We are working on additional indications focusing on products with high commercial and social impact.

Vaccines

Phase 1 completed. Polymersomes formulated with spike protein co- administered with polymersomes formulated CpG 7909, as a Covid booster vaccine.

Respiratory

Polymersomes formulated with CpG 7909 administered therapeutically to reduce hospitalization from viral pneumonia infections.

Oncology

Polymersomes carrying TLR agonists as targeted immunotherapy. IND approved for first in human polymersome-CpG therapy.

A growing pipeline comprising targeted delivery of TLR agonists as vaccines and therapies against infectious diseases, respiratory infections and cancer.

At ACM Biolabs we are driven to change the status quo necessitated by the limitations of current delivery technologies. We are focused on leveraging the strengths of the ATP™technology to improve the effectiveness of TLR agonists against diverse illnesses.Thereafter we will broaden the focus to other modalities.
Development Ph I
Infectious Disease
SARS-CoV-2 vaccine w CpG 7909
Respiratory Infection
TLR7/8 w/wo CpG 7909
* Platform Clinical Validation
** IIT with National Cancer Center Singapore (NCCS)
Documented achievements.

“Development of Thermostable and Immunogenic Block Copolymer Nanoparticles (BNPs) for mRNA Delivery”
·View
“Production of Recombinant Viral Antigens Using the Baculovirus-Insect Cell Expression System”
·View
“Intranasal COVID vaccine that works against variants in animals”
09. November 2022
·View
“Artificial Cell Membrane Polymersome-Based Intranasal Beta Spike Formulationas a SecondGenerationCovid-19Vaccine”
09. November 2022
·View
view more
“CEPI partnership – Boosting access to mRNA vaccines through innovative mRNA delivery platform”
·View
“Cambridge’s DIOSynVax and Singapore’s ACM Biolabs to Advance Pandemic-Ready Universal Bird Flu Vaccine with International Support”
·View
“ACM Biolabs shines at NTUitive’s Technology Roadshow 2023”
16. October 2023
·View
“ACM Biolabs Announces Positive Topline Results from a Phase I Trial of SARS-CoV-2 Booster Vaccine ACM-001”
05. September 2023
·View
view more

[email protected]

Contact us for any questions regarding business development.

[email protected]

Contact us for any questions regarding science, studies or general office matters.

ACM Biolabs Pte Ltd

71 Nanyang Drive, #02M-02 NTU Innovation Centre, Singapore 638075
Phone: +65 6265 5646

ACM Biolabs Pty Ltd

139 Macquarie Street

ACM Biosciences AG

Career Opportunities

We are currently building a high quality and motivated team to develop our polymer-based delivery technology and bring innovative medicines to patients with high unmet medical need. Working at the intersection of pre-clinical and clinical research as a part of multidisciplinary team We we are looking for candidates with expertise in mRNA technologies, nano-technology, chemistry of lipids- and polymer-based delivery formulations and analytical methods. Interested applicants should please forward their resumé / CV to [email protected]
Career Opportunities
Madhavan Nallani
Founder | Chief Executive Officer | Chief Scientific Officer
Chairman of the Board ACM Biolabs & ACM Biosciences
Business Development
Developed the core intellectual property of the company while working in Germany, the Netherlands and Singapore (at the Institute of Materials Research & Engineering (IMRE, A*STAR) and also at Nanyang Technological University).
Pierre Vandepapelière
Clinical Advisor
Pharmacologist. Vaccines Expert with more than 30 years of experience of R&D.
Doctorat at the Université catholique de Louvain, Belgium. Leading function at GSK, Abivax, NeoVacs, Imcyse, and Amyl Therapeutics. CEO at Vaccibio Consulting.
Director of the Board ACM Biolabs
Founder of the Erber Group, an Austrian animal nutrition company (now part of DSM), which consists of more than 50 affiliates in all continents. He is also founder of the SAN Pacific Investments Group. Recipient of numerous awards including the Austrian Export award and Ernst & Young Entrepreneur of the Year and is an Honorary Senator of the University of Veterinary Medicine and the University of Natural Resources and Applied Life Sciences, Vienna.
Erich is the key investor representative on ACM Biolabs’ Board of Directors.
Director of the Board ACM Biolabs
Sang Bin is currently the managing director of Ritz Venture Capital, a Singapore based family fund that focuses in supporting early-stage companies. He has over 30 years of experience in venture investments as well as mentorship within the academic community. With his background in engineering and business, he is a strong supporter of applying cutting edge technology and cultivating talents to address some of the key challenges in the world in the near future.
Director of the Board ACM Biolabs Australia
Maria leverages 15 years’ experience as founder and CEO of an ASX listed biotechnology company, and a prior 10 years in corporate finance and venture capital, assisting early-stage companies with capital raising, scale -up and international expansion. Recognised for her experience in funding and commercialising technologies internationally, Maria executed several cross-border mergers and acquisitions, opened new markets, built multidisciplinary teams, led digital transformation and navigated companies through complex regulatory environments. An experienced non-executive director and contributor to the start-up ecosystem, Maria is a Graduate of the University of Western Australia and the Australian Institute of Company Directors, she is a Non-executive Director of the Garvan Research Foundation, Member of Women on Boards, Ausbiotech and Women in Media, Connector at Apropela and a past Councilor at the Australian Industry Group. A lifelong running enthusiast Maria has a keen interest in lifespan expansion and healthy longevity and is passionate about taking others along a healthy longevity journey.
Scientific Advisor
Clinical Immunologist, Scientific Advisor
Professor & Chair, Clinical Immunology, University of Zurich, Director, Department of Immunology, University Hospital Zurich.
Corporate Affairs
PhD. Managed the Micro- and Nano-systems group of 50 R&D staff in the Singapore research institute where the polymersome technology originated. Thereafter, co-founded Singular ID, a successful tech start-up which received funding from institutional investors based in the US, Europe and Asia and was acquired by a multinational. Has worked with Dr Nallani on ACM since 2011.
Katherine Schultheis
Head of Discovery Research
Katherine Schultheis joined ACM Biosciences in 2022 as Head of Discovery Research with a strong background of preclinical development of DNA based vaccines and immunotherapeutics. Katherine has more than 10 years of academic and corporate research experience in the fields of infectious diseases, autoimmunity and oncology. She was heading a research team at Inovio Pharmaceuticals in San Diego, California, before moving back to the greater Basel area in 2021. Katherine obtained her Master’s level degree in Biochemistry from University of Potsdam, Germany.
Finance and Admin Manager
Before joining ACM Biolabs, Qiwei was an audit manager with experience in SMEs and subsidiaries of MNCs of various industries. He is also a member of the Institute of Singapore Chartered Accountants and CPA Australia.
Prior to joining ACM Biolabs, Melvin received his PhD in Materials Science and Engineering from Nanyang Technological University in 2023. His PhD research focused on the fabrication and characterization of biomimetic nanoparticles for drug and RNA delivery.
Principal Scientist
Dr. Liu received her PhD in chemical and biomolecular engineering from National University of Singapore (NUS). She has more than 15 years of research and development experience in Biomedical science and Bioengineering. She has generated 5 patents and 42 papers in reputable journals including Nature communications and Advanced Materials.
Senior Scientist
Jian Hang Lam holds a Ph.D. from the Yong Loo Lin School of Medicine, National University of Singapore. He was trained in pre-clinical dengue vaccine development and gained experience in virology and immunology, with special focus on investigating correlates of protection.
Senior Scientist
Ser Yue Loo is a Senior Scientist at ACM Biolabs. Prior to joining ACM Biolabs, Ser Yue carried out her postdoctoral fellowship at Genome Institute of Singapore, where she conducted research on therapeutics for treatment of triple negative breast cancer. Her work led to the successful translation from bench to bedside with the initiation of a clinical trial BEXMET in National Cancer Centre Singapore.
Loo Ser Yue obtained her PhD from Yong Loo Lin School of Medicine at National University of Singapore in 2014.
Gaurav Sinsinbar
Senior Scientist
Gaurav joined ACM Biolabs in 2021, after completing his PhD research in the field of point-of-care diagnostics from the School of Material Science and Engineering at NTU.
Yan Jun Lee is a Scientist at ACM Biolabs. She obtained her PhD from Nanyang Technological University, Singapore in 2021. She then carried out her postdoctoral fellowship at National University of Singapore. She has conducted neuroscience studies in molecular and system settings throughout her academics training.
Anivind Kaur Bindra
Anivind Kaur Bindra is a Scientist at ACM Biolabs. She obtained bachelor’s and master’s degrees in Chemistry from University of Delhi, India in 2015. Thereafter, from her research internship at Defence Research and Development Organization, India, she got interested into the cancer drug delivery field. She further pursued Ph.D. in Chemistry from Nanyang Technological University, Singapore in 2021. During Ph.D. and Postdoctoral training, her research interests included the design and development of functional organic-inorganic hybrid nanomaterials for nanomedicine.
Formulation Developmental Scientist
Graduated from Nanyang Technological University in 2019 with a Bachelor’s Degree in Chemistry and Biological Chemistry. Joined ACM Biolabs in 2019 as a Research Assistant.
Salmah Humairoh Binte Zamri
Research Assistant
Research Assistant at ACM Biolabs with a Bachelor of Engineering in Bioengineering obtained in 2024 from Nanyang Technological University.
Research Assistant
Research Assistant at ACM Biolabs. Obtained a diploma in Chemical Engineering in 2015 and Bachelor’s Degree in Chemistry and Biological Chemistry in 2021 at Nanyang Technological University.
Eunice Yoong Eng Chia
Research Assistant
Research Assistant at ACM Biolabs. Obtained a diploma in Medicinal Chemistry in 2017 and a degree of Bachelor of Science in Chemistry and Biological Chemistry in 2021 at Nanyang Technological University.”